Literature DB >> 18987823

Methylation-specific PCR.

Julien D F Licchesi1, James G Herman.   

Abstract

Methylation-specific polymerase chain reaction (MSP) is a technique that has facilitated the detection of promoter hypermethylation at CpG islands in cell lines and clinical samples, including fresh/frozen tissues. The ability of MSP to differentiate methylated from unmethylated cytosine is dependent upon sodium bisulfite treatment of DNA which retains the methylation marks of cytosines together with the specific amplification of this modified DNA using primer sets complimentary only to the formerly methylated or unmethylated alleles. Nested-MSP (MN-MSP) is an alternative method that overcomes the limitations of MSP, especially when it comes to analyzing samples with low quality/quantity of starting DNA (e.g., paraffin-embedded specimens). MN-MSP includes a first round of amplification using primers unbiased toward the methylation status of a single (MN-MSP) or multiple (multiplex MN-MSP) genes followed by conventional MSP. Although MSP and NM-MSP are simple techniques that can easily be incorporated in most molecular biology laboratories, the ability to accurately determine the promoter methylation status of genes largely depends upon the careful design of MSP primers as well as other steps outlined in this chapter.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18987823     DOI: 10.1007/978-1-59745-522-0_22

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  21 in total

1.  Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.

Authors:  Eric Schafer; Rafael Irizarry; Sandeep Negi; Emily McIntyre; Donald Small; Maria E Figueroa; Ari Melnick; Patrick Brown
Journal:  Blood       Date:  2010-03-09       Impact factor: 22.113

2.  Association of the hypermethylation status of PTEN tumor suppressor gene with the risk of breast cancer among Kurdish population from Western Iran.

Authors:  Kheirollah Yari; Mehrdad Payandeh; Zohreh Rahimi
Journal:  Tumour Biol       Date:  2015-12-29

3.  MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck.

Authors:  Scott M Langevin; Roslyn A Stone; Clareann H Bunker; Maureen A Lyons-Weiler; William A LaFramboise; Lori Kelly; Raja R Seethala; Jennifer R Grandis; Robert W Sobol; Emanuela Taioli
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

4.  Assays for hypermethylation of the BRCA1 gene promoter in tumor cells to predict sensitivity to PARP-inhibitor therapy.

Authors:  Ilsiya Ibragimova; Paul Cairns
Journal:  Methods Mol Biol       Date:  2011

5.  Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.

Authors:  Teena Bhatla; Jinhua Wang; Debra J Morrison; Elizabeth A Raetz; Michael J Burke; Patrick Brown; William L Carroll
Journal:  Blood       Date:  2012-04-11       Impact factor: 22.113

6.  Epigenetic silencing of CXCL14 induced colorectal cancer migration and invasion.

Authors:  Baoping Cao; Yunsheng Yang; Yuanming Pan; Yan Jia; Malcolm V Brock; James G Herman; Mingzhou Guo
Journal:  Discov Med       Date:  2013-10       Impact factor: 2.970

Review 7.  DNA methylation of cancer genome.

Authors:  Hoi-Hung Cheung; Tin-Lap Lee; Owen M Rennert; Wai-Yee Chan
Journal:  Birth Defects Res C Embryo Today       Date:  2009-12

Review 8.  DNA methylation changes in prostate cancer: current developments and future clinical implementation.

Authors:  Mohammad Obaidul Hoque
Journal:  Expert Rev Mol Diagn       Date:  2009-04       Impact factor: 5.225

Review 9.  Epigenetics as a therapeutic target in breast cancer.

Authors:  Roisin Connolly; Vered Stearns
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-07-27       Impact factor: 2.673

10.  Region of interest methylation analysis: a comparison of MSP with MS-HRM and direct BSP.

Authors:  Reem Akika; Zainab Awada; Nahed Mogharbil; Nathalie K Zgheib
Journal:  Mol Biol Rep       Date:  2017-07-04       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.